Galmed Pharma AGM Adjourned Due to Lack of Quorum
Ticker: GLMD · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Galmed Pharma's shareholder meeting postponed to Oct 29 due to no quorum. Big decisions on hold.
AI Summary
Galmed Pharmaceuticals Ltd. (the "Company") announced that its Annual General Meeting of Shareholders, originally scheduled for October 28, 2025, was adjourned for one day due to a lack of quorum. The meeting will now reconvene on Wednesday, October 29, 2025, at 4:00 p.m. Israel time at the offices of Meitar Law Offices.
Why It Matters
The adjournment of the shareholder meeting may indicate a lack of engagement from major shareholders or potential disagreements, which could impact future corporate decisions.
Risk Assessment
Risk Level: low — The adjournment is a procedural matter and does not inherently signal financial distress or operational failure.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- October 28, 2025 (date) — Original meeting date
- October 29, 2025 (date) — Reconvened meeting date
- Meitar Law Offices (company) — Legal counsel and meeting location
FAQ
Why was the Annual General Meeting of Shareholders adjourned?
The meeting was adjourned due to a lack of quorum.
When will the adjourned Annual General Meeting of Shareholders reconvene?
The meeting will reconvene on Wednesday, October 29, 2025.
What time will the reconvened meeting take place?
The meeting will take place at 4:00 p.m. Israel time.
Where will the reconvened meeting be held?
The meeting will be held at the offices of Meitar Law Offices.
What is the Commission File Number for Galmed Pharmaceuticals Ltd.?
The Commission File Number is 001-36345.
Filing Stats: 258 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-10-28 16:05:13
Filing Documents
- form6-k.htm (6-K) — 16KB
- 0001493152-25-019879.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: October 28, 2025 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer